Diabetes, diabetes risk factors and treatments, and breast cancer  by Boyle, P.
Parallel Session Abstracts
2013 e133
assessment (RA), which involves examining the intrinsic toxicity of 
an agent (hazard assessment) and comparing it with the anticipated 
human exposure to characterize the likelihood of adverse effects (risk 
characterization). Although this process is meant to integrate all data 
sources (human, environmental, in vivo, in vitro, in silico), in practice 
existing regulations of pharmaceutical and chemical substances con-
tinue to ask for sector-specific RAs, each of which has its own specific 
information requirements and uses different methods for the ultimate 
risk quantification. Although regulators often stress the primacy of 
human data, in practice their use is constrained by availability and 
lack of defined quality criteria. There have been some efforts in the 
past to develop frameworks for the use of human data (eg, from 
poison centers) for risk assessment purposes. However, these have 
had only limited success. More recently, integrated approaches have 
been developed using information from animal studies and human 
data based on mode of action and weight of evidence concepts. These 
approaches need to be tested and validated. Harmonized data col-
lection based on defined quality criteria is a precondition for better 
use of human data in risk assessment. It will only become a reality if 
existing networks of institutions such as poison control and clinical 
toxicology centers are being strengthened and, importantly, if they 
interact with regulatory decision makers on a regular basis. This 
will result in enhanced sharing of knowledge, build consensus, and 
facilitate clear, easily understood, transparent, and unambiguous inte-
grated RA procedures. Network initiatives such as the EU FP7 project 
HEROIC aim to contribute to the development of such harmonized 
approaches that meet the challenges of RA.
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Clinical pharmacology in Russia was established 13 years after the 
first World Health Organization (WHO) manifesto describing its 
duties was released. In 1983, it was defined as a separate educational 
discipline in medical universities. Starting from 1997, the medical 
specialty “clinical pharmacologist” was established, and its func-
tions were defined. It was built on the union of pharmacology and 
internal medicine, and that is why clinical pharmacology in Russia 
is characterized by close proximity to routine patient care. A clini-
cal pharmacologist in Russia should first receive training in internal 
medicine and then 2-year specialization in clinical pharmacology. 
The current main duties of clinical pharmacologists in Russia are 
defined by the ministerial laws released in 2003 and 2010, updated 
in 2012. According to these documents, clinical pharmacologists 
should see patients and be able to adjust treatment by taking into 
account various possible factors of individual response to medica-
tions. They should advise when necessary and interpret results of 
pharmacogenetic analyses; perform therapeutic drug monitoring and 
drug interaction analyses; and diagnose, register, and manage adverse 
drug reactions. Furthermore, clinical pharmacologists should manage 
quality control of medications used in their hospitals, participate in 
drug and therapeutics committees, develop and maintain a system of 
formulary lists of medications, perform drug utilization surveillance, 
participate in microbiology monitoring in relation to antibiotic utili-
zation, define economic feasibility of different medications use, and 
approve purchase of drugs according to the general hospital needs. 
They should also provide informational services to physicians and 
patients on various issues of rational drug use.
According to the current law, every medical institution should 
have a position of clinical pharmacologist; hospitals with > 500 
beds are advised to have a corresponding division. This provides 
grounds for active development of the specialty and improvement 
of educational programs. Some universities have courses of clini-
cal pharmacology included in the curriculum of other specialists. 
Since 2009, clinical pharmacologists in Russia are cooperating 
within the all-Russian “Association of Clinical Pharmacologists” 
comprising the vast majority or regions. The association is per-
forming important organizational, informational and expert func-
tions.
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Summary: To clarify the potential association between diabetes, 
related factors, treatments, and breast cancer risk, a series of meta-
analyses was carried out following PRISMA guidelines. For breast 
cancer at all ages, the risks obtained from prospective studies were: 
diabetes (SRR = 1.27 [95% CI, 1.16 to 1.39]); physical activity (SRR 
= 0.88 [0.85 to 0.92]); glycemic load (SRR = 1.05 [1.00 to 1.10]); 
glycemic index (SRR = 1.05 [1.00 to 1.09]); fasting glucose (SRR 
= 1.14 [0.94 to 1.37]); serum insulin (SRR = 1.11 [0.75 to 1.85]); 
c-peptide (SRR = 1.00 [0.69 to 1.46]), and adiponectin (SRR = 1.16 
[0.93 to 1.46]). An increase of 5 units in BMI was associated with 
postmenopausal breast cancer (SRR = 1.12 [95% CI, 1.08 to 1.16]) 
but not at premenopausal ages (SRR = 0.83 [95% CI, 0.72 to 0.95]). 
Serum insulin and c-peptide were associated with breast cancer at 
postmenopausal ages but not at premenopausal. For IGF-1, Hodge’s 
standardized mean difference (HSMD) was calculated, and there was 
no significant association with breast cancer (HSMD = 0.026 [95% 
CI, –0.031 to 0.084]).
The SRR for breast cancer among users of insulin glargine was 
1.08 (0.98 to 1.20) and was 0.92 (0.32 to 2.65) when restricted to 
randomized trials. Among new users, the SRR for breast cancer was 
1.09 (0.98, 1.21), and there was no trend of increasing breast cancer 
risk with increasing duration of use of glargine (β = 0.04) (P = 0.52). 
Risk of breast cancer in a prospective cohort declined with increasing 
follow-up, from 1.99 (1.31, 2.03) with 2 years of follow-up, to 1.60 
(1.10 to 2.32) with 3 years, 1.50 (1.10 to 2.10) with 4 years and 1.18 
(0.84 to 1.66) with 5 years of follow-up. There is no reduction in risk 
of breast cancer associated with metformin use (SRR = 0.96 [95% 
CI, 0.85 to 1.08]) even for the longest duration of use (SRR = 0.94 
[95% CI, 0.81 to 1.09]).
An association between these 2 common diseases could have 
important implications for public health, with common risk factors 
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driving further increases in both diseases yet holding the tantalizing 
possibility for prevention of both.
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Summary: Noninfectious uveitis is a sight-threatening, immune-
mediated intraocular inflammatory disorder. Posterior uveitis can 
involve the retina, choroid, vitreous, and optic nerve. Uveitis can 
result from heterogeneous numerous etiologies, including infectious, 
autoimmune causes, and tumoral-mimicking uveitis. Infectious and 
tumoral causes need specific treatment. Primary or secondary autoim-
mune disorders of posterior ocular segment require anti-inflamma-
tory treatment to prevent from visual loss.
Uveitis is responsible for ~10% of the visual handicap.
Immunodepressive treatment is required in sight-threatening 
noninfectious posterior uveitis. Nowadays, corticosteroid therapy 
remains the first-line conventional treatment for active, noninfec-
tious uveitis. Corticosteroids could be administered by peri or intra-
ocular injection, using intravitreal implant, or systemically. The limit 
od intra-ocular steroid are side effects as secondary glaucoma and 
a short time therapeutic activity needing re-injection or bilateral 
injection for bilateral chronic uveitis. Therefore, posterior chronic 
bilateral uveitis is still nowadays treated with an oral steroid such 
as prednisone. If the daily dose threshold is greater than ~0.2 mg/
kg/d of prednisone, a combination of immunosuppressive or immu-
nomodulator drugs is indicated, both for their own immunosuppres-
sive and steroid-sparing capabilities.
Immunosupressive agents, conventionally used in its indication, can 
be categorized into 3 main classes: T-cell inhibitors (cyclosporine, tac-
rolimus), antimetabolites (azathioprine, methotrexate, mycophenolate 
mofetil, leflunomide), and alkylating agents (cyclophosphamide, chloram-
bucil). All had been shown efficient in severe uveitis. Side effects include 
increased risk of infection, hematologic toxicity, sterility, and secondary 
malignancy. Moreover, immunosuppressive drugs can exhibit selective 
tissue toxicity as renal toxicity induced by cyclosporine treatment.
The risk of severe side effects of immunosuppressive drugs has 
led to the evaluation of the therapeutic benefit of immunomodulator 
drugs such as polyclonal antibodies and interferon alpha. The thera-
peutic benefit of INFa in Behcet’s disease was recently documented in 
a meta-analysis of both systemic disease control and uveitis control. 
The frequency of ocular attacks was significantly reduced compared 
with the pretreatment observation period, and there was a significant 
steroid-sparing effect. A randomized prospective study has been done 
using 3 arms - with only steroids systemic therapy - with only inf 
alpha systemic therapy – under only observation, for 4 months, in the 
chronic noninfectious posterior uveitis associated to macular edema. 
The main criteria was the central foveal thickness, an objective, repro-
ductible parameter measured through optical coherence tomography, 
a noninvasive tool. The results will be presented in the conference.
Trial Randomized multicentric trial. Code number P051032. 
Biomedical research Phase II with individual direct benefit.. 
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